Zura Bio Limited - Class A Ordinary shares (ZURA)

$6.00 0.81 (15.61%)

16:00 EDT ZURA Stock Quote Delayed 30 Minutes

ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024

By InvestorPlace Earnings May 9, 2024

ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024.

ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023

Why Is Zura Bio (ZURA) Stock Up 9% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 397,224

Day's Range $5.18 - $6.20

52-Week Range $2.00 - $13.00

Dividend & Yield N/A (N/A)

ZURA Stock Predictions, Articles, and Zura Bio Limited - Class A Ordinary shares News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Mar 24, 2023

It's time to start off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Friday!

ZURA Stock Alert: Zura Bio SPAC Merger Rally Ends

By William White, InvestorPlace Writer Mar 23, 2023

Zura Bio (ZURA) stock is on the move Thursday following the clinical-stage biotechnology company's public debut earlier this week.

ZURA Stock Alert: Low-Float Zura Bio Rockets 300%

By Samuel O'Brient, InvestorPlace Reporter Mar 22, 2023

After a shaky trading debut, ZURA stock has been skyrocketing all day. However, its low float may raise some concerns.

Redx to Quit London Stock Exchange’s AIM, Citing Low Liquidity

From Bloomberg Apr 2, 2024

Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.

Zura Bio appoints industry veteran Robert Lisicki as President and COO (NASDAQ:ZURA)

From Seeking Alpha Jan 8, 2024

Zura Bio (NASDAQ:ZURA) has appointed Robert Lisicki as President and Chief Operating Officer.Mr.

Oppenheimer starts Zura Bio at outperform, cites potential of ZB-106 (NASDAQ:ZURA)

From Seeking Alpha Aug 25, 2023

Oppenheimer has initiated coverage of Zura Bio (ZURA) with an outperform rating, citing the revenue potential of its drug ZB-106, also known as tibulizumab. Read more here.

Zura Bio to join Russell 2000 and Russell 3000 indexes (NASDAQ:ZURA)

From Seeking Alpha Jun 23, 2023

Zura Bio (ZURA) to be added to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on...

Why Shares of Zura Bio Climbed Tuesday

From The Motley Fool Jun 20, 2023

The biotech stock continued its rise in June.

Zura Bio climbs 7% as director buys stock (NASDAQ:ZURA)

From Seeking Alpha Jun 6, 2023

Zura Bio (ZURA) Director, Amit Munshi acquires ~118K shares on June 5, 2023 at a price of $4.25 per share, worth ~$500K.This brings his total share holdings to ~617K.The stock price...

ADVERTISEMENT